M Schulz1, J Wacker, G Bastert. 1. Universitäts-Frauenklinik, Heidelberg. michael_schulz@med.uni-heidelberg.de
Abstract
OBJECTIVE: For the therapy of preeclamptic patients is Urapidil besides Dihydralazine another possible option for iv-therapy with good results in first clinical studies. Effects of both drugs on the newborns were observed. - METHODS: The maternal and fetal Urapidil plasma-concentrations and cardiovascular parameters of the newborns were observed in a randomised comparative therapy-study. - RESULTS: We found low fetal Urapidil plasma-concentrations as well as a less influence on cardiovascular parameters compared to dihydralazine. - DISCUSSION: With Urapaidil we have another therapeutic option in preeclampsia where we could not show any negative side-effects on the newborns.
RCT Entities:
OBJECTIVE: For the therapy of preeclamptic patients is Urapidil besides Dihydralazine another possible option for iv-therapy with good results in first clinical studies. Effects of both drugs on the newborns were observed. - METHODS: The maternal and fetal Urapidil plasma-concentrations and cardiovascular parameters of the newborns were observed in a randomised comparative therapy-study. - RESULTS: We found low fetal Urapidil plasma-concentrations as well as a less influence on cardiovascular parameters compared to dihydralazine. - DISCUSSION: With Urapaidil we have another therapeutic option in preeclampsia where we could not show any negative side-effects on the newborns.